Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.

Yahya Ashraf | Hanane Mansouri | Valérie Laurent-Matha | Lindsay B Alcaraz | Pascal Roger | Séverine Guiu | Danielle Derocq | Gautier Robin | Henri-Alexandre Michaud | Helène Delpech | Marta Jarlier | Martine Pugnière | Bruno Robert | Anthony Puel | Lucie Martin | Flavie Landomiel | Thomas Bourquard | Oussama Achour | Ingrid Fruitier-Arnaudin | Alexandre Pichard | Emmanuel Deshayes | Andrei Turtoi | Anne Poupon | Joëlle Simony-Lafontaine | Florence Boissière-Michot | Nelly Pirot | Florence Bernex | William Jacot | Stanislas du Manoir | Charles Theillet | Jean-Pierre Pouget | Isabelle Navarro-Teulon | Nathalie Bonnefoy | André Pèlegrin | Thierry Chardès | Pierre Martineau | Emmanuelle Liaudet-Coopman
Journal for immunotherapy of cancer | 2019

Triple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC are urgently needed. Immunotherapy is emerging as an exciting treatment option for TNBC patients. The aspartic protease cathepsin D (cath-D), a marker of poor prognosis in breast cancer (BC), is overproduced and hypersecreted by human BC cells. This study explores whether cath-D is a tumor cell-associated extracellular biomarker and a potent target for antibody-based therapy in TNBC.

Pubmed ID: 30717773

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Promega (tool)

RRID:SCR_006724

An Antibody supplier

View all literature mentions

Thermo Fisher Scientific (tool)

RRID:SCR_008452

Commercial vendor and service provider of laboratory reagents and antibodies. Supplier of scientific instrumentation, reagents and consumables, and software services.

View all literature mentions

FlowJo (tool)

RRID:SCR_008520

Software for single-cell flow cytometry analysis. Its functions include management, display, manipulation, analysis and publication of the data stream produced by flow and mass cytometers.

View all literature mentions

Stata (tool)

RRID:SCR_012763

A Software resource for statistical analysis and presentation of graphics.

View all literature mentions

Abcam (tool)

RRID:SCR_012931

A commercial antibody supplier which supplies primary and secondary antibodies, biochemicals, proteins, peptides, lysates, immunoassays and other kits.

View all literature mentions

Dako (tool)

RRID:SCR_013530

An Antibody supplier; Dako was purchased by Agilent in 2012 and several years later the websites began to reflect the Dako products as part of the Agilent catalog.

View all literature mentions

ImageScope (tool)

RRID:SCR_014311

Slide image modification software that allows the user to adjust the magnification, compare slides, pan and zoom, annotate specific areas, and perform image analysis of digital slides. Users can create macros and algorithms to automate analysis and create plots, respectively.

View all literature mentions

MODELLER (tool)

RRID:SCR_008395

Software tool as Program for Comparative Protein Structure Modelling by Satisfaction of Spatial Restraints. Used for homology or comparative modeling of protein three dimensional structures. User provides alignment of sequence to be modeled with known related structures and MODELLER automatically calculates model containing all non hydrogen atoms.

View all literature mentions

MDA-MB-231 (tool)

RRID:CVCL_0062

Cell line MDA-MB-231 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions